Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock
In addition, Inozyme has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less the underwriting discounts and commissions.
- In addition, Inozyme has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less the underwriting discounts and commissions.
- All of the shares of common stock are being offered by Inozyme.
- BofA Securities, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering.
- 333-258702) relating to the shares of common stock offered in the public offering was filed with the Securities and Exchange Commission (the “SEC”) on August 11, 2021 and became effective on August 23, 2021.